# A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT

> **NCT03190733** · PHASE4 · UNKNOWN · sponsor: **Zhujiang Hospital** · enrollment: 192 (estimated)

## Conditions studied

- Chronic Graft-versus-host-disease
- Leukemia Relapse

## Interventions

- **DRUG:** ATG

## Key facts

- **NCT ID:** NCT03190733
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-30
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2017-06-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190733, "A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03190733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*